Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol

INTRODUCTION: Enzalutamide and abiraterone acetate plus prednisolone (AAP) are used in combination with androgen-deprivation therapy to further suppress the androgen stimulation of metastatic castration-resistant prostate cancer (mCRPC). First-line mCRPC treatment with enzalutamide and AAP yields si...

Descripción completa

Detalles Bibliográficos
Autores principales: Kvorning Ternov, Klara, Sønksen, Jens, Fode, Mikkel, Lindberg, Henriette, Kistorp, Caroline Michaela, Bisbjerg, Rasmus, Palapattu, Ganesh, Østergren, Peter Busch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747677/
https://www.ncbi.nlm.nih.gov/pubmed/31511288
http://dx.doi.org/10.1136/bmjopen-2019-030218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747677/
https://www.ncbi.nlm.nih.gov/pubmed/31511288
http://dx.doi.org/10.1136/bmjopen-2019-030218

Ejemplares similares